Human immunodeficiency virus (HIV), the causative
Los Angles, as pneumocystis pneumonia in 1981. Since agent of acquired immunodeficiency syndrome (AIDS) [1] [2] [3] [4] , then, AIDS has become the most devastating disease that now infects an estimated 60 million people worldwide, out mankind has ever faced. India ranks second after South of which 4 million are in India. Cure has not yet been Africa in the number of people with HIV infection. found for this fatal disease. Rapid advances in molecular Tuberculosis is the leading opportunistic infection in HIV biology, along with 3-D elucidation of HIV protein, have positive persons. The AIDS epidemic is one of the greatest led to new drug-targeting approaches for designing challenges being faced by the medical community. Infection antiviral agents that specially bind key regulatory with HIV is a dynamic process characterized by vigorous proteins that are essential for HIV replication. The HIV-1 viral replication, CD4 lymphocyte depletion and profound protease is one such enzyme crucial for maturation and immunodeficiency. The error-prone nature of HIV reverse assembly of infectious viral particles. Thus by inhibiting transcriptase promotes rapid evolution of genetic diversity HIV-1 protease activity [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , a potential cure for AIDS is at and a remarkable propensity to develop resistance to hand. Armed with 3-D crystal structure of HIV-1 antiretroviral agents. Improved understanding of viral protease, rational drug design approaches have been widely employed in the development of HIV protease inhibitors; while in clinical trials, existent HIV-1 protease inhibitors show promise in causing an initial dramatic decline in viral plasma RNA in HIV-infected individuals, most patients taking protease inhibitors alone. Failure of HIV-1 protease inhibitor therapy is attributed to the development of resistant viral protease.
AIDS, the acquired immunodeficiency syndrome, was first reported in the Morbidity and Mortality Weekly Report, The X-ray structure showed that 4 hydroxy group of has now become the most important issue in the treatment coumarin ring forms hydrogen bonds with two key of HIV infection.
catalytic aspartic residues (Asp 25 and Asp 25´), and two oxygen of lactone ring form hydrogen bonds with Structure and function of HIV protease:
isoleucine residues, thus replacing the water molecule of Through X-ray crystallography techniques, the 3-D peptide-type inhibitors bound to HIV protease. During structure of HIV-1 protease has been extensively studied lead optimization, the phenyl and ethyl groups on and characterized. In its mature form, the viral protease compound (3) each occupied a peptide-binding pocket. exists as a dimer, whose subunits each consists of 99
The rigid coumarin ring on the other hand prevented amino acids. The folded subunits together interact to form access to good binding to additional sites; thus, a core hydrophobic, cylindrical catalytic cavity (24 A long substituted dihydropyran analogues were investigated. × 6-8 A in diameter) and two flexible flaps (one per unit) that can close around the substrate. Centred in the Initial approaches for developing HIV-1 protease hydrophobic active sites are two symmetrically disposed inhibitors were based on characterizing substrate catalytic aspartyl residues (Asp 25 and Asp 25') that are protease. The first generation of HIV protease inhibitors involved in the hydrolysis of the peptide bond 29 . Studies are peptidomimetic compounds containing transition state have shown that the hydrophobic cavern can hold six inserts in place of dipeptide cleavage sites of natural amino acids of the substrate in an extended conformation substrates for viral enzyme. Optimization of peptide leads for cleavage. Because structural and enzymatic proteins of HIV virus are translated as part of two polyprotein precursors (Gag and Gag/Pol), cleavage of these precursors to generate gag matrix (p17), capsid (p24), nucleocapsid (p15) protein, Pol reverse transcriptase, integrase enzymes and other viral proteins is vital for the production of mature infectious viral particles 30 .
Since this cleavage process is critical to viral propagation, inhibition of viral protease proves to be an attractive drug target. Protease inhibitors act by binding reversibly to the active site of HIV proteases. This prevents the proteases from cleaving the viral precursor polypeptide and blocks subsequent viral maturation. Most HIV protease inhibitors have poor absorption, poor oral bioavailability, short produced potent protease inhibitor PNU-75875 (1) having extremely poor pharmacokinetic properties. Anticoagulant warfarin (2) selected as a lead had only weak enzyme inhibitory activity. another related compound phenprocoumon (3) having improved potency, both having excellent pharmacokinetic properties. Kinetic analysis of phenprocoumon indicated that it was a competitive inhibitor of HIV protease. Substituted pyrone analogues were investigated, leading to first generation clinical candidate PNU-96988 (4); it was at least 25 times more potent than the original lead template phenprocoumon. The modelling hypothesis that increasing the flexibility of coumarin nucleus in compound (2) www.ijpsonline.com analogues PNU-103017 (6). Based upon drug design, additional binding site was realized by attaching an amide group at the meta position of C-3 phenyl group (7). Further modelling based on the structure of compound (7) bound to HIV protease suggested that replacement of the amide carbonyl with an SO 2 group (8) could result in an additional hydrogen bonding; subsequent optimization of the sulphonamide moiety led to clinical candidate PNU 140690 (5) bound in the active site of HIV protease. It revealed that there was a small pocket in the enzyme that permitted the favourable insertion of para-cyano group, a ring resulted in highly potent protease inhibitors. Dichloro-substituted analogues appeared to be one of the most potent compounds. However, they found that dichloro-substituted analogues were less potent than methyl-or chloro-substituted analogues due to smaller size, while methyl-substituted pyridyl methyl amides were found less active than 3-pyridyl analogues. Five membered heterocycles (oxazole and thiazole) were also studied. They found thiazole derivatives comparable to the most potent substituted phenyl analogues. Nagaranjan et al. 38 reported that inhibitors incorporate a variety of small electron-withdrawing moiety. It was discovered that isosters including the hydroxy ethylurea at the protease cellular activity of PNU-103017 was greatly reduced when cleavage site. They found that replacement of t-butylurea human serum protein was added to cell culture, and high moiety with benzothiazolesulfonamide resulted in potent protein binding limited its effectiveness; therefore, search and improved inhibitors (15) 36 reported that non-peptide HIV where 2,5-disubstituted pyrrolidine (18) based HIV protease inhibitor phenprocouman (3), previously protease inhibitors with improved antiviral potency identified as lead template, led to the identification of first through modification at P1. These analogues generation drug candidate compound (4) . Further demonstrated antiviral efficacy comparable to currently molecular modelling studies based on crystal structures of marketed agents (amprenavir). P1-substituted phenols HIV protease inhibitor complexes suggested the demonstrated similar or increased enzyme inhibition incorporation of carboxamide functionality at the meta relative to the unsubstituted analogue, and each of P1 position of the benzyl side chain at C-3-carboxamide analogues with the exception of benzyl analogue containing 4-hydroxy-2-pyrone compound (7) showed demonstrated increased antiviral activity. The derivatives improved inhibitory activity, and replacement of of compound (18) demonstrated somewhat improved carboxamide group with sulphonamide functionality antiviral efficacy relative to the marketed protease resulted in non-peptide compounds with improved activity. The most active diasteromer of compound (11) showed potent protease inhibitory activity with a k i value of 0.5 µM. Cyclooctylpyranone derivatives with m carboxamide substituents were identified as potent non peptide HIV protease inhibitors, but these compounds lacked significant antiviral activity in cell culture.
SAR of protease inhibitors:
Lu et al. 37 prepared hybrid inhibitors (14) by combining the P3P2P1 ligand of a hydroxy amide based inhibitor JE 2147 (13) with P1P3 portion of indinavir (12) . They reported the SAR study of lead. Replacement of one of the methyl group with an electronegative atom on phenyl inhibitor amprenavir. Stranix et al. 41 reported the synthesis of new series of lysine sulfonamide analogues bearing N ε-benzylic ureas (19) using both solution and solid phase approach through novel synthetic route Nα (alkyl)-Nα-(sulfonamide)lysinol using α-aminocaprolactam. Synthesized compounds were novel protease inhibitors with high potency against wild type HIV virus. Huang et al. 42 reported the synthesis of novel azacyclic urea (20,21) HIV protease inhibitors bearing a benzene sulfonamide group at P1 using parallel synthesis method. They did structural studies of early analogues bound in enzyme active sites to design more potent inhibitors. They also reported the effects of substituting P1 benzenesulfonyl group on antiviral activity and protein ( w w w www.ijpsonline.com www.ijpsonline.com binding. Skulnick et al. 43 reported that substitution of a sulfonamide group at the meta position produces compounds with excellent HIV protease binding affinity and antiviral activity. They prepared and evaluated a number of these derivatives; a few of the most of the compounds were further evaluated. p cyanophenylsulphonamide derivatives emerged as promising inhibitors and entered phase I clinical trials. Boyer et al. 44 synthesized a series of compounds which possess various sulfonyl moieties substituted at 4-position of C-3-phenyl ring, substituent of dihydropyran-2-one ring projects polar meta substituent into bound water. They 
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uniquely accommodate both high enzyme potency and which provide platform for fine tuning of drug-like properties in this class of PIs by additional chemical manipulations on the meta position.
CONCLUSION
So far, the modifications of non-peptide protease inhibitors have proven highly effective, and modifications that have been made so far do not exhaust the possible changes that can be made to improve the potency and efficacy of these non-peptide protease inhibitors. It would be interesting to see whether these derivatives can be utilized as potent antiHIV in future. ) .
